About this trial
This study aims to examine whether the AI-personalized version of the Medilepsy® app is more effective than the non-AI (standard version without AI personalization) can improve key outcomes, such as medical adherence and transition readiness, among underserved adolescents and young adults with epilepsy, ages 14-24, in Florida, USA.
Outcomes are organized into primary (effectiveness), secondary (usability), and exploratory (language experience) endpoints.
Eligibility criteria
Qualifiers
Diagnosed with epilepsy
Currently prescribed anti-seizure medicine (ASMs)
Identified as part of an underserved population, defined as meeting at least one of the following: member of a racial or ethnic group historically underrepresented in research or healthcare or low-income status (e.g., eligible for public assistance or government-subsidized health coverage)
Are between 14-17 years old and able to provide assent, with a parent or LAR present to receive app notifications throughout the study
Disqualifiers
They do not own a mobile device with internet access.
They have a history of severe intellectual disability.
They are unable to operate a mobile device (keyboard or touchscreen).
Reside in an in-patient setting.
Trial design
Treatments tested in this trial
- Medilepsy® Chatbot AI-Enhanced
- Medilepsy® Chatbot Standard
Treatment groups
Locations
2Sponsors and collaborators
University of Central Florida
Lead sponsor
American Epilepsy Society
Collaborator
Orlando Regional Medical Center
Collaborator
Orlando Health Arnold Palmer Hospital
Collaborator